Abstract
The complexity of the central nervous system (CNS) exposes it to a number of different diseases, often caused by only small variations in gene sequence or expression level. Antisense oligonucleotides and RNA interference-mediated therapies hold great promise for the treatment of CNS diseases in which neurodegeneration is linked to overproduction of endogenous protein or to synthesis of aberrant proteins coded by dominant mutant alleles. Nevertheless, difficulties related to the crossing of the blood-brain barrier, expression vectors, molecule design and to the choosing of the correct target, should be effectively solved. This review summarizes some of the most recent findings concerning the administration of potential nucleic acid-based therapeutic drugs, as well as the most promising studies performed both in vitro and in animal models of disease. Finally, some current clinical trials involving antisense oligonucleotides or silencing RNA for therapy of neurological disorders are illustrated. Results of current studies and clinical trials are exciting, and further results will be certainly reached with increasing knowledge of blood-brain barrier transporters, of genes involved in neurological disease and in new vectors for efficient delivery to brain.
Keywords: antisense oligonucleotides, rna interference, small interfering rna, brain cancer, genetic disorders, gene delivery tools, blood brain barrier, clinical trials
Current Drug Targets
Title: Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Volume: 6 Issue: 1
Author(s): A. Forte, M. Cipollaro, A. Cascino and U. Galderisi
Affiliation:
Keywords: antisense oligonucleotides, rna interference, small interfering rna, brain cancer, genetic disorders, gene delivery tools, blood brain barrier, clinical trials
Abstract: The complexity of the central nervous system (CNS) exposes it to a number of different diseases, often caused by only small variations in gene sequence or expression level. Antisense oligonucleotides and RNA interference-mediated therapies hold great promise for the treatment of CNS diseases in which neurodegeneration is linked to overproduction of endogenous protein or to synthesis of aberrant proteins coded by dominant mutant alleles. Nevertheless, difficulties related to the crossing of the blood-brain barrier, expression vectors, molecule design and to the choosing of the correct target, should be effectively solved. This review summarizes some of the most recent findings concerning the administration of potential nucleic acid-based therapeutic drugs, as well as the most promising studies performed both in vitro and in animal models of disease. Finally, some current clinical trials involving antisense oligonucleotides or silencing RNA for therapy of neurological disorders are illustrated. Results of current studies and clinical trials are exciting, and further results will be certainly reached with increasing knowledge of blood-brain barrier transporters, of genes involved in neurological disease and in new vectors for efficient delivery to brain.
Export Options
About this article
Cite this article as:
Forte A., Cipollaro M., Cascino A. and Galderisi U., Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases, Current Drug Targets 2005; 6 (1) . https://dx.doi.org/10.2174/1389450053344920
DOI https://dx.doi.org/10.2174/1389450053344920 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drugs and Aggression
Recent Patents on CNS Drug Discovery (Discontinued) A Review of the Chemical and Pharmacological Aspects of the Genus Marrubium
Current Pharmaceutical Design Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism Understanding the Cardiovascular Actions of Soy Isoflavones: Potential Novel Targets for Antihypertensive Drug Development
Cardiovascular & Hematological Disorders-Drug Targets Prodrug Design Targeting Intestinal PepT1 for Improved Oral Absorption: Design and Performance
Current Drug Metabolism Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Stenting and Prevention of Ischemic Stroke
Current Drug Targets Propofol: Therapeutic Indications and Side-Effects
Current Pharmaceutical Design Peptide Therapeutics in Neurodegenerative Disorders
Current Medicinal Chemistry Osteoporotic Fracture Healing: Potential Use of Medicinal Plants from the Tropics
Current Drug Targets Phytochemicals as Adjunctive with Conventional Anticancer Therapies
Current Pharmaceutical Design Vascular Endothelium and Hypovolemic Shock
Current Vascular Pharmacology Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Multidetector Computed Tomography of Iatrogenic Urinary Trauma - Pictorial Review
Current Medical Imaging Triterpenes from Gloeophyllum odoratum as Potential Leads Towards Potent Thrombin Inhibitors
Letters in Drug Design & Discovery Role of Cyclic Tertiary Amine Bioactivation to Reactive Iminium Species: Structure Toxicity Relationship
Current Drug Metabolism Synthesis of Dihydropyridines: Patented Catalysts and Biological Applications
Recent Patents on Catalysis (Discontinued) CB Receptor Ligands from Plants
Current Topics in Medicinal Chemistry Editorial [ Hot Topic:Addiction and Pain: Cannabinoid and Opioid Interactions (Guest Editor: Sonia Tucci) ]
Current Drug Targets New Trends in Thromboxane and Prostacyclin Modulators
Current Medicinal Chemistry